Northwestern Mutual Wealth Management Co. Sells 64,703 Shares of Pfizer Inc. $PFE

Northwestern Mutual Wealth Management Co. trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 11.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 514,459 shares of the biopharmaceutical company’s stock after selling 64,703 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Pfizer were worth $12,388,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Cullinan Associates Inc. grew its position in Pfizer by 11.3% during the second quarter. Cullinan Associates Inc. now owns 51,301 shares of the biopharmaceutical company’s stock valued at $1,235,000 after acquiring an additional 5,200 shares during the last quarter. Greenwood Capital Associates LLC increased its holdings in Pfizer by 4.1% during the 2nd quarter. Greenwood Capital Associates LLC now owns 58,299 shares of the biopharmaceutical company’s stock valued at $1,404,000 after purchasing an additional 2,300 shares during the period. Delta Asset Management LLC TN lifted its stake in Pfizer by 1.9% in the second quarter. Delta Asset Management LLC TN now owns 105,462 shares of the biopharmaceutical company’s stock worth $2,540,000 after acquiring an additional 2,016 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Pfizer by 4.7% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 36,157,306 shares of the biopharmaceutical company’s stock valued at $870,668,000 after purchasing an additional 1,634,374 shares in the last quarter. Finally, New Mexico Educational Retirement Board raised its position in shares of Pfizer by 7.9% in the 2nd quarter. New Mexico Educational Retirement Board now owns 282,800 shares of the biopharmaceutical company’s stock worth $6,810,000 after acquiring an additional 20,800 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently weighed in on PFE. Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective for the company in a research report on Tuesday, June 9th. JPMorgan Chase & Co. decreased their price objective on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 8th. Wolfe Research reaffirmed an “underperform” rating and issued a $26.00 target price on shares of Pfizer in a report on Thursday, May 14th. HSBC downgraded shares of Pfizer from a “buy” rating to a “hold” rating and reduced their target price for the stock from $32.00 to $28.00 in a report on Monday, July 6th. Finally, Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $28.28.

Pfizer Price Performance

NYSE PFE opened at $29.02 on Thursday. The company has a market cap of $165.42 billion, a PE ratio of 38.19, a P/E/G ratio of 1.92 and a beta of 0.34. The firm’s 50 day moving average price is $25.79 and its 200-day moving average price is $26.32. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. Pfizer Inc. has a 52-week low of $23.58 and a 52-week high of $29.09.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same quarter in the prior year, the business earned $0.78 earnings per share. Pfizer’s revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th were given a $0.43 dividend. The ex-dividend date of this dividend was Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 5.9%. Pfizer’s payout ratio is presently 226.32%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Strong quarterly performance: Pfizer reported earnings and revenue above expectations, with quarterly revenue increasing year over year. The results, along with growth in vaccines and oncology, have helped drive renewed investor interest. Pfizer Stock Surges to 52-Week Peak Following Strong Q2 Results and Major Legal Settlement
• Positive Sentiment: Legal overhang reduced: Pfizer’s reported settlement of more than 6,000 Depo-Provera lawsuits removes some litigation uncertainty and may be viewed favorably by investors. Pfizer Stock Surges to 52-Week Peak Following Strong Q2 Results and Major Legal Settlement
• Positive Sentiment: Pipeline activity: Pfizer has begun a Phase 1 study of asthma candidate PF-08103402. Although early-stage programs are not near-term revenue drivers, the trial provides another potential growth asset as the company works to offset future patent expirations. Pfizer’s New Asthma Candidate PF-08103402 Enters Phase 1
• Neutral Sentiment: Valuation and dividend appeal: A bullish investment case argues that PFE remains attractive below $30 for patient, income-oriented investors, supported by its dividend and long-term recovery potential. Should You Buy Pfizer Stock Below $30?
• Negative Sentiment: Growth concerns persist: Commentary highlights declining core-business revenue and the approaching patent cliff. Pfizer’s AI strategy is viewed as a longer-term promise rather than evidence of immediate earnings growth. Can AI Save Pfizer Stock Before Its Patent Cliff Hits?
• Negative Sentiment: Bearish sentiment remains visible: Jim Cramer declined to recommend Pfizer despite its dividend, while unusually high put-option activity suggests some traders are positioning for downside or hedging near the recent high. Cramer Won’t Recommend Pfizer Even With Its Dividend

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.